key: cord-0969392-e982hr41
authors: Xiang, Tiandan; Liang, Boyun; Wang, Hua; Quan, Xufeng; He, Shengsong; Zhou, Helong; He, Yongwen; Yang, Dongliang; Wang, Baoju; Zheng, Xin
title: Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection
date: 2021-11-15
journal: Cell Mol Immunol
DOI: 10.1038/s41423-021-00795-5
sha: cedd3b516838cae6a5e74e2cd88a817052d2dd35
doc_id: 969392
cord_uid: e982hr41

nan

20 CHB patients with abnormal alanine aminotransferase levels [61.5 (43-129) U/L] or 10 patients with compensated liver cirrhosis. The results demonstrated that SARS-CoV-2 inactivated vaccines had a favorable safety profile in CHB patients. Given that previous studies have shown an increased risk of progression to severe disease in COVID-19 patients with cirrhosis [7] , the benefit of vaccination in compensated cirrhotic patients still outweighs the vaccine-related risk.

Next, we determined the immunogenicity of CHB patients who completed the two doses of the vaccination regimen. The seropositivity for anti-S-RBD-IgG and NAbs was 87.25% and 74.5%, respectively (Fig. 1A) . The anti-S-RBD-IgG seropositivity of CHB vaccine recipients was similar to that in a clinical trial of CoronaVac in Turkey (89.7%) but much higher than the reported recently seropositivity of IgG antibodies to the spike protein (76%) in patients with chronic liver disease [5] . Both anti-S-RBD-IgG and NAb levels increased significantly to a higher level after completing the vaccination regimen ( Fig. 1B , C, P < 0.0001). This finding indicates that SARS-CoV-2 inactivated vaccines can elicit an optimal antibody response even though some CHB patients may have pre-existing compromised immune function.

The seropositivity and antibody titers in CHB patients were further compared according to sex, age, antiviral therapy, and body mass index stratification (Fig. 1D , E). We found that younger patients (<40 y) had higher seropositivity for anti-S-RBD-IgG (P < 0.05), and female patients exhibited increased seropositivity for NAbs (P < 0.05). Recent clinical trials have also reported a similar trend: younger individuals and female vaccine recipients exhibited stronger humoral immune responses to vaccination [2] . Interestingly, the patients undergoing nucleos(t)ide analog therapy had a significantly higher NAb titer than those who were not (P < 0.05) (Fig. 1D , E). Long-term antiviral therapy can inhibit viral replication and facilitate the restoration of the impaired immune system by recovering the function of circulating dendritic cells, natural killer cells, or T cells, particularly nucleotide analogs that can induce the production of IFN-λ3 [6, 8] . These factors may account for the higher antibody titer in patients with antiviral therapy. Given that nucleos(t)ide analog therapy does not affect vaccine-induced immune responses, it should be continuously administered during vaccination to avoid negatively impacting CHB treatment. [9] . Sample numbers and positive rates are shown underneath. P values were determined using a Mann-Whitney U test or a Kruskal-Wallis test followed by Dunn's multiple comparisons test for antibody titers and Fisher's exact test for seropositivity. The horizontal dotted line represents the cutoff value. ns: no significance, *p < 0.05, ****p < 0.0001

Finally, we compared the antibody responses among the CHB patients in the various clinical stages of infection. The CHB participants were divided into four groups according to the "EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection" [9] : (I) HBeAg-positive chronic HBV infection, (II) HBeAg-positive chronic hepatitis B, (III) HBeAg-negative chronic HBV infection, and (IV) HBeAg-negative chronic hepatitis B. There was no significant difference in seropositivity or antibody titers among the four groups constituting the 149 CHB patients (Fig. 1F,  G) , suggesting the general applicability of the inactivated vaccines within this patient population.

Altogether, our study reveals that SARS-CoV-2 inactivated vaccines achieve a favorable safety profile and efficient immunogenicity in patients with CHB in real-world vaccination scenarios. The results are encouraging despite some patients not being vaccinated following the standard dose interval time in clinical trials or the two dosages of the inactivated vaccine not being from the same manufacturer.

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study

Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases

Recovery of circulating CD56(dim) NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg

High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry

Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

Clinical Practice Guidelines on the management of hepatitis B virus infection

XZ, BJW, TDX, and BYL designed and conceived the study; TDX, BYL, and HW performed the experiments; TDX, BYL, HW, XFQ, HLZ, YWH, DLY, BJW, and XZ enrolled patients and acquired the data; BYL and HW analyzed the data and contributed to producing the charts; TDX drafted the manuscript; XZ and BJW revised the manuscript.

The authors declare no competing interests.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41423-021-00795-5.Correspondence and requests for materials should be addressed to Baoju Wang or Xin Zheng.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.